Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

1. A unit dosage formulation comprising 25.0% by weight of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof, 25.7% by weight of refined polydextrose, 25.0% by weight of mannitol, 12.8% by weight of polyethylene glycol 3350, 3.7% by weight of poloxamer 407 powder, 5.0% by weight of crospovidone, and less than 2% by weight of one or more excipients selected from hydroxyethyl cellulose, vanilla flavor, non-bovine magnesium stearate or colloidal silica.

2. The unit dosage formulation of claim 1 , comprising 125 mg to 1000 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.

3. The unit dosage formulation of claim 1 , comprising 250 mg to 1000 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.

4. The unit dosage formulation of claim 1 , comprising 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, or 1000 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.

5. The unit dosage formulation of claim 1 , wherein the unit dosage formulation is packaged in plastic bottles.

6. The unit dosage formulation of claim 1 , wherein the unit dosage formulation is a powder or granules packaged in a sachet.

7. A suspension comprising the unit dosage formulation of claim 1 , wherein the suspension has a concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof selected from 25 mg/mL or 50 mg/mL.

8. The suspension of claim 7 , wherein the suspension is in water, milk, a carbonated beverage, juice, apple sauce, baby food or baby formula.